Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study

Table 7 Expression of miRNAs in the miR-17-92 cluster and paralogues according to molecular subtype, using PCR

MiRNA	Molecular subtype	Mean (SD)	Contrasts	p*
miR-17-5p	Luminal A	− 5.49 (0.73)	Luminal A vs others	0.066
	Luminal B	− 4.93 (1.43)	Luminal B vs others	0.65
	HER2+	− 5.03 (1.70)	HER2+ vs others	0.58
	Triple-negative	− 3.26 (0.95)	Triple-negative vs others	0.0025
miR-20a-5p	Luminal A	1.72 (0.68)	Luminal A vs others	0.066
	Luminal B	2.21 (1.18)	Luminal B vs others	0.67
	HER2+	2.15 (1.19)	HER2+ vs others	0.65
	Triple-negative	3.45 (1.03)	Triple-negative vs others	0.0053
miR-92a-3p	Luminal A	1.44 (0.74)	Luminal A vs others	0.070
	Luminal B	1.75 (1.00)	Luminal B vs others	0.58
	HER2+	1.89 (0.97)	HER2+ vs others	0.85
	Triple-negative	2.87 (0.90)	Triple-negative vs others	0.0073
miR-106b-5p	Luminal A	− 0.014 (0.55)	Luminal A vs others	0.12
	Luminal B	0.30 (1.11)	Luminal B vs others	0.65
	HER2+	0.54 (1.44)	HER2+ vs others	0.91
	Triple-negative	1.10 (0.84)	Triple-negative vs others	0.070
miR-93-5p	Luminal A	1.20 (0.73)	Luminal A vs others	0.070
	Luminal B	1.78 (0.97)	Luminal B vs others	0.93
	HER2+	1.85 (1.21)	HER2+ vs others	0.91
	Triple-negative	2.37 (1.03)	Triple-negative vs others	0.085

Expression levels are presented as mean (standard deviation) of normalized PCR quantification cycle (Cq) values based on the average of the normalizer assay detected in all samples and the formula: normalized Cq = average Cq (all samples) − assay Cq (sample). Negative PCR expression values indicate lower expression levels compared to the normalizer
* False discovery rate (FDR) adjusted p-value for contrast tests comparing miRNA expression levels in one molecular subtype of cancers to the other cancers grouped together. E indicates exponential number

ISSN: 1479-5876